Peptidream Inc. 4587

Completion of patient dosing in the registrational Phase 2 clinical trial for 64Cu-PSMA-I&T - a PET radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) expressed on prostate cancer cellsData analysis is now underway to support future regulatory submission in Japan BOSTON, June 11, 2026 (GLOBE NEWSWIRE) -- Curium Group announced today that together with PeptiDream Inc. and PDRadiopharma Inc., patient dosing has been completed in the registrational Phase 2 clinical trial for 64

PeptiDream’s latest analyst update centers on a sharp reset in the 12 month price target, cut from ¥2,700 to ¥1,600. Bulls argue this lower target now better matches the current pace of out licensing and turns the recent downgrade to Neutral into more of a sentiment reset. Bears, however, see it as a sign of reduced conviction around monetizing the pipeline. As you read on, you will see what this shift could mean for expectations and how to track the story as new licensing milestones...